Method Profile
Organoids and primary cells obtained from the same tumor provide paired material for structural and molecular comparisons, with an exploratory two-patient temozolomide experiment.
Preserving matched two- and three-dimensional tumor models for mechanistic and drug-response research.
Fifteen glioblastoma organoid models established from 18 patient samples, with primary tumor cells recovered from material collected during preparation.
Paired organoids and primary cells assessed by morphology, staining, representative matched sequencing and longitudinal projected-area measurements.
Patient-derived tumor material
Eighteen glioblastoma specimens within a collection of 22 central nervous system tumor specimens.
Drug comparison
Organoids from two patients tested with 160 μM temozolomide or DMSO vehicle.
Retain the matched relationships between tumor, original organoid, passaged organoid and recovered material. Drug exposure lasts one week followed by two weeks of observation after withdrawal, with growth measured by projected area.
Representative structural and molecular checks, a two-patient organoid drug comparison and exploratory clinical follow-up.
Establishment: 15 of 18 glioblastoma samples. Drug testing: two patient-derived models with three organoid replicates per treatment. Sequencing overlap figures describe the presented matched comparisons.
Matched tumor tissue, original/passaged/recovered organoids, primary cells from the comparison isolation method and vehicle-treated organoids.
Approximately 83% establishment success and substantial variant overlap in the representative comparisons; the two tested organoid models showed different degrees of temozolomide-associated growth response.
An academic team established organoids from 15 of 18 glioblastoma samples and recovered matched primary cells during processing. A two-patient temozolomide comparison illustrates exploratory use of the models, with very limited clinical follow-up.
